プログラム

第 11 回武田科学振興財団薬科学シンポジウム

* Alphabetical order in each session.as of June 10, 2021
Optical Imaging / Therapy
Chemical Probes for Imaging of Hydrolases in Cancer and Infectious Diseases
Matthew Bogyo
Stanford University School of Medicine, U.S.A.
Near infrared photoimmunotherapy of cancer
Hisataka Kobayashi
National Cancer Institute, NIH, U.S.A
Molecular optical imaging probes as Artificial Biomarkers for early diagnosis and optical urinalysis
Kanyi Pu
Nanyang Technological University, Singapore
Therapeutic ln Vivo Synthetic Chemistry
Katsunori Tanaka
Tokyo Institute of Technology, Japan
Live imaging-based identification of cancer specific biomarker enzymatic activities and their therapeutic applications
Yasuteru Urano
The University of Tokyo, Japan
Chemical probes for imaging immune cell function
Marc Vendrell
The University of Edinburgh, U.K.
Porphyrin Nanomedicine for Cancer Imaging and Therapy
Gang Zheng
University of Toronto, Canada

Radiopharmaceuticals for Diagnosis and Therapy
Studies of targeted alpha therapy in Osaka University: development of At-211 labeled radiotherapeutics
Koichi Fukase
Osaka University, Japan
FAP-Ligand in Cancer Disease
Frederik L. Giesel
University Hospital Heidelberg, Germany
Boron Neutron Capture Therapy and Targeted Alpha Therapy: New Radiotherapy Strategy with LAT1 Molecules and PET
Jun Hatazawa
Osaka University, Japan
Targeted Thorium Conjugates (TTCs) – a new approach in Targeted Alpha Therapies (TAT)
Hartwig H. Hennekes
Bayer AG, Germany
A Pretargeted Approach to Radiotheranostics
Jason S. Lewis
Memorial Sloan Kettering Cancer Center, U.S.A
Targeted and non targeted effects of targeted radionuclide therapy
Jean-Pierre Pouget
Institute de Recearch en Cancérologie de Montpellier (Inserm), France

Molecular MRI / Theranostics
New Insights Towards an Improved Characterization of Tumours
Silvio Aime
University of Torino, Italy
Functional and theranostic contrast agents for MRI
Ichio Aoki
National Institutes for Quantum and Radiological Science and Technology, Japan
Applications of Molecular Imaging to the Development of Anti-Fibrotic Therapies
Peter Caravan
Harvard Medical School, U.S.A
Magnetic Particle Imaging: Engineering, Applications, and Tracers
Steve Conolly
University of California Berkeley, U.S.A
Imaging brain activity with molecular MRI probes
Alan P. Jasanoff
Massachusetts Institute of Technology, U.S.A
Nano-particle based sensitive 19F MRI contrast agent with tunable chemical switches
Kazuya Kikuchi
Osaka University, Japan
MRI of the Changing Brain or MRI Contrast for Detecting Single Cells
Alan P. Koretsky
National Institute of Neurological Disorders and Stroke, NIH, U.S.A